J. Soubirou, Témocilline, une alternative aux carbapénèmes pour traiter les infections à entérobactéries résistantes aux C3G ?, J. Anti-Infect, vol.15, pp.60-70, 2013.

R. Vanhoof, Comparative in vitro activity of temocillin and other antimicrobial agents against Enterobacteriaceae isolated from patients admitted to five Belgian hospitals, Acta Clin. Belg, vol.56, pp.354-359, 2001.

S. Barker, Temocillin: a new candidate antibiotic for local antimicrobial delivery in orthopaedic surgery?, J. Antimicrob. Chemother, vol.70, pp.780-783, 2015.

. Eumedica, NEGABAN 1g, résumé des caractéristiques du produit, vol.12, 2014.

. Eumedica, NEGABAN 2g, résumé des caractéristiques du produit, vol.12, 2014.

E. A. Guest, Human pharmacokinetics of temocillin (BRL 17421) side chain epimers, J. Antimicrob. Chemother, vol.15, pp.327-336, 1985.

A. C. Miranda-bastos, S. J. Vandecasteele, P. M. Tulkens, A. Spinewine, and F. Van-bambeke, Development and validation of a high performance liquid chromatography assay for the determination of temocillin in serum of haemodialysis patients, J. Pharm. Biomed. Anal, vol.90, pp.192-197, 2014.

G. Burton, C. R. Dobson, and J. R. Everett, The degradation of temocillin, a 6 alpha-methoxypenicillin, and identification of the major degradation products, J. Pharm. Pharmacol, vol.38, pp.758-761, 1986.

A. Matagne, J. Lamotte-brasseur, G. Dive, J. R. Knox, and J. M. Frère, Interactions between active-siteserine beta-lactamases and compounds bearing a methoxy side chain on the alpha-face of the betalactam ring: kinetic and molecular modelling studies, Biochem. J, vol.293, pp.607-611, 1993.

R. De-jongh, Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection, J. Antimicrob. Chemother, vol.61, pp.382-388, 2008.

S. Carryn, N. Couwenbergh, and P. M. Tulkens, Long-term stability of temocillin in elastomeric pumps for outpatient antibiotic therapy in cystic fibrosis patients, J. Antimicrob. Chemother, vol.65, pp.2045-2046, 2010.

K. Jules and H. C. Neu, Antibacterial activity and beta-lactamase stability of temocillin, Antimicrob. Agents Chemother, vol.22, pp.453-460, 1982.

H. Rodriguez-villalobos, In vitro activity of temocillin against extended spectrum beta-lactamaseproducing Escherichia coli, J. Antimicrob. Chemother, vol.57, pp.771-774, 2006.

J. M. Adams-haduch, B. A. Potoski, H. E. Sidjabat, D. L. Paterson, and Y. Doi, Activity of temocillin against KPC-producing Klebsiella pneumoniae and Escherichia coli, Antimicrob. Agents Chemother, vol.53, pp.2700-2701, 2009.

Y. Glupczynski, In vitro activity of temocillin against prevalent extended-spectrum betalactamases producing Enterobacteriaceae from Belgian intensive care units, Eur. J. Clin. Microbiol. Infect. Dis. Off. Publ. Eur. Soc. Clin. Microbiol, vol.26, pp.777-783, 2007.

H. M. Just, In vitro combination-effect of temocillin with ticarcillin and aminoglycosides on gramnegative and gram-positive bacteria, Drugs, vol.29, pp.74-77, 1985.

D. M. Livermore, What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline, Int. J. Antimicrob. Agents, vol.37, pp.415-419, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00685788

S. Henquet, La témocilline : une alternative aux carbapénèmes ? Etude de la sensibilité des enterobactéries, 2013.

Y. Yang and D. M. Livermore, Activity of temocillin and other penicillins against beta-lactamase-inducible and-stably derepressed enterobacteria, J. Antimicrob. Chemother, vol.22, pp.299-306, 1988.
DOI : 10.1093/jac/22.3.299

P. C. Fuchs, A. L. Barry, C. Thornsberry, and R. N. Jones, Interpretive criteria for temocillin disk diffusion susceptibility testing, Eur. J. Clin. Microbiol, vol.4, pp.30-33, 1985.
DOI : 10.1007/bf02148656

D. Fournier, Alternatives to carbapenems in ESBL-producing Escherichia coli infections, Med. Mal. Infect, vol.43, pp.62-66, 2013.
URL : https://hal.archives-ouvertes.fr/hal-00802661

B. Pangon, In vivo selection of a cephamycin-resistant, porin-deficient mutant of Klebsiella pneumoniae producing a TEM-3 beta-lactamase, J. Infect. Dis, vol.159, pp.1005-1006, 1989.

J. D. Pitout, Infections with extended-spectrum beta-lactamase-producing enterobacteriaceae: changing epidemiology and drug treatment choices, Drugs, vol.70, pp.313-333, 2010.
DOI : 10.2165/11533040-000000000-00000

I. Balakrishnan, Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and/or derepressed AmpC ?-lactamase-producing Enterobacteriaceae, J. Antimicrob. Chemother, vol.66, pp.2628-2631, 2011.

D. M. Livermore, Activity of temocillin against prevalent ESBL-and AmpC-producing Enterobacteriaceae from south-east England, J. Antimicrob. Chemother, vol.57, pp.1012-1014, 2006.

N. Woodford, In vitro activity of temocillin against multidrug-resistant clinical isolates of Escherichia coli, Klebsiella spp. and Enterobacter spp., and evaluation of high-level temocillin resistance as a diagnostic marker for OXA-48 carbapenemase, J. Antimicrob. Chemother, vol.69, pp.564-567, 2014.

N. T. Mutters, S. Zimmermann, M. Kaase, and A. Mischnik, Activity of temocillin, mecillinam, ceftazidime, and ceftazidime/avibactam against carbapenem-non-susceptible Enterobacteriaceae without carbapenemase production, Eur. J. Clin. Microbiol. Infect. Dis. Off. Publ. Eur. Soc. Clin. Microbiol, vol.34, pp.2429-2437, 2015.

G. A. Jacoby and I. Carreras, Activities of beta-lactam antibiotics against Escherichia coli strains producing extended-spectrum beta-lactamases, Antimicrob. Agents Chemother, vol.34, pp.858-862, 1990.

B. Slocombe, BRL 17421, a novel beta-lactam antibiotic, highly resistant to beta-lactamases, giving high and prolonged serum levels in humans, Antimicrob. Agents Chemother, vol.20, pp.38-46, 1981.

N. D. Gupta, R. E. Smith, and I. Balakrishnan, Clinical efficacy of temocillin, J. Antimicrob. Chemother, vol.64, pp.431-433, 2009.

S. J. Vandecasteele, Thrice-weekly temocillin administered after each dialysis session is appropriate for the treatment of serious Gram-negative infections in haemodialysis patients, Int. J. Antimicrob. Agents, vol.46, pp.660-665, 2015.

Z. Modr, Pharmacokinetics of temocillin after intravenous and intramuscular administration, Czech. Med, vol.9, pp.181-186, 1986.

P. Laterre, Temocillin (6 g daily) in critically ill patients: continuous infusion versus three times daily administration, J. Antimicrob. Chemother, vol.70, pp.891-898, 2015.

B. Hampel, M. Feike, P. Koeppe, and H. Lode, Pharmacokinetics of temocillin in volunteers, Drugs, vol.29, pp.99-102, 1985.

J. S. Legge, T. M. Reid, and J. Palmer, Clinical efficacy, tolerance and pharmacokinetics of temocillin in patients with respiratory tract infections, Drugs, vol.29, pp.118-121, 1985.

F. Spelsberg, A. Bauernfeind, W. Wiest, and P. Hanser, Biliary concentrations of temocillin. Drugs, vol.29, pp.122-127, 1985.

G. J. Poston, A. Greengrass, and C. J. Moryson, Biliary concentrations of temocillin. Drugs, vol.29, issue.5, pp.140-145, 1985.

D. Overbosch, C. Van-gulpen, and H. Mattie, Renal clearance of temocillin in volunteers, Drugs, vol.29, issue.5, pp.128-134, 1985.

R. R. Wittke, D. Adam, and H. E. Klein, Therapeutic results and tissue concentrations of temocillin in surgical patients, Drugs, vol.29, pp.221-226, 1985.

J. Boelaert, Effect of renal function and dialysis on temocillin pharmacokinetics, Drugs, vol.29, issue.5, pp.109-113, 1985.

H. W. Asbach, E. Becker-boost, and M. Melekos, Clinical evaluation of temocillin in urinary tract infections, Drugs, vol.29, pp.175-177, 1985.

E. R. Weissenbacher, K. Gutschow, A. Bauernfeind, and H. G. Luehr, Temocillin treatment of gynaecological infections with special reference to blood and tissue concentrations, Drugs, vol.29, pp.178-181, 1985.

G. Reimer, R. Milbradt, F. W. Hulla, and D. Kammacher, Single dose therapy with temocillin in acute gonorrhoea, Drugs, vol.29, pp.210-212, 1985.

K. Ismaili, Characteristics of first urinary tract infection with fever in children: a prospective clinical and imaging study, Pediatr. Infect. Dis. J, vol.30, pp.371-374, 2011.

B. Nunn, A. Baird, and P. D. Chamberlain, Effect of temocillin and moxalactam on platelet responsiveness and bleeding time in normal volunteers, Antimicrob. Agents Chemother, vol.27, pp.858-862, 1985.

M. Kazi, A. Shetty, and C. Rodrigues, The carbapenemase menace: do dual mechanisms code for more resistance?, Infect. Control Hosp. Epidemiol, vol.36, pp.116-117, 2015.

G. Meletis, E. Protonotariou, D. Papadopoulou, and L. Skoura, Comment on: The Carbapenemase Menace: Do Dual Mechanisms Code for More Resistance?, Infect. Control Hosp. Epidemiol, vol.37, pp.1392-1394, 2016.

H. Rodriguez-villalobos, Trends in production of extended-spectrum beta-lactamases among Enterobacteriaceae of clinical interest: results of a nationwide survey in Belgian hospitals, J. Antimicrob. Chemother, vol.66, pp.37-47, 2011.

, Rapport de surveillance des bacteries multiresistantes dans les etablissements de santé en France (resultats, 2014.

A. P. Wilson, Sparing carbapenem usage, J. Antimicrob. Chemother, vol.72, pp.2410-2417, 2017.

R. Mélanie, Audit des pratiques sur le Centre Hospitalier St Joseph St Luc à Lyon. Place de la témocilline dans les propositions d'améliorations

, Annexe 2 : Stabilité de la témocilline dans des dispositifs à libération prolongée en élastomère

, Sensibilité des souches de Klebsiella pneumoniae et d'Escherichia coli possédant des ßlactamases de type KPC à la témocilline, Annexe, vol.3

, Annexe 4 : Effet inoculum sur l'activité de la témocilline

, Annexe 5 : CMI de la témocilline pour différentes souches de laboratoire

, Comparaison de l'activité de la témocilline par rapport à celle d'autres antibiotiques dont la cefoxitine sur 12 espèces d'Enterobacteriaceae différentes, Annexe, vol.6

, Annexe 7 : Sensibilité des souches sauvages et mutantes aux pénicillines

, Activité in vitro de la témocilline contre 2280 souches d'Escherichia coli, de Klebsiella spp et d'Enterobacter spp, Annexe, vol.8

, Classifications moléculaire et fonctionnelle des ß-lactamases (AC: acide clavulanique et TZB: Tazobactam), vol.9

, Distribution des souches Escherichia coli productrices de BLSE en fonction de leur CMI pour 12 antibiotiques différents, Annexe, vol.12

, Distribution des CMI des souches d'Enterobacteriaceae à la témocilline en fonction des ?lactamases produites (Angleterre), Annexe, vol.13

, Tableau de corrélation entre les résultats des prélèvements bactériologiques, l'antibiothérapie par témocilline et les antécédents des différents patients de l'étude, vol.17